U.S. market Closed. Opens in 10 hours 12 minutes

LVTX | LAVA Therapeutics N.V. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 1.6100 - 1.7982
52 Week Range 1.3500 - 6.47
Beta 0.76
Implied Volatility 540.80%
IV Rank 33.57%
Day's Volume 32,848
Average Volume 48,222
Shares Outstanding 26,292,200
Market Cap 46,800,116
Sector Healthcare
Industry Biotechnology
IPO Date 2021-03-26
Valuation
Profitability
Growth
Health
P/E Ratio -2.00
Forward P/E Ratio N/A
EPS -0.89
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 37
Country Netherlands
Website LVTX
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
*Chart delayed
Analyzing fundamentals for LVTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see LVTX Fundamentals page.

Watching at LVTX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on LVTX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙